| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-08-2024 | 03-31-2024 | 10-Q | |
| 2 | 03-28-2024 | 12-31-2023 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Robert Burns reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $25 price ...
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Robert Burns initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and an...
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...
Fiscal Year 2023 Financial ResultsResearch and development expenses were $64.9 million and $30.4 million for the years ended De...
Jefferies analyst Kelly Shi initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Tar...
Citigroup analyst Yigal Nochomovitz initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces P...
Goldman Sachs analyst Corinne Johnson initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces...
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
